Completed PHASE2 INTERVENTIONAL NCT00001785

Recombinant Human Interferon Beta-1a (Avonex) for the Treatment of Patients With HTLV-1-Associated Myelopathy (HAM)

Combined Virological and Immunological Evaluation of Treatment of Patients With Early HTLV-1-Associated Myelopathy With Recombinant Human Interferon Beta-1a

Sponsor: National Institute of Neurological Disorders and Stroke (NINDS)

Conditions HTLV-I Infection Spinal Cord Disease Tropical Spastic Paraparesis

Interventions Recombinant human interferon beta-1a

Updated 5 times since 2017 Last updated: Mar 3, 2008 Started: Sep 30, 1998 Completion: Sep 30, 2004

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates HTLV-I Infection and Spinal Cord Disease and is currently completed. National Institute of Neurological Disorders and Stroke (NINDS) leads this study, which shows 5 recorded versions since 1998 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Sep 1998

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

National Institute of Neurological Disorders and Stroke (NINDS)

Data source: National Institutes of Health Clinical Center (CC)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Bethesda, United States